MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients With Triple Negative or HER2+ MBC

Triple Negative Breast Cancer Clinical Trial

— SYMPToM  

Official title:

Routine MRI Screening Versus Symptom-directed Surveillance for Brain Metastases Among Patients With Triple Negative and HER2+ Metastatic Breast Cancer (MBC): A Single-centre Randomized Pilot Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03881605
• Other study ID #: 211-2018
• Status: Recruiting
• Phase: N/A
• Start date: November 8, 2018
• Est. completion date: June 2021

Study information

• Verified date: March 2019
• Source: Sunnybrook Health Sciences Centre
• Contact: Katarzya J Jerzak, MD MSc FRCPC
• Phone: 4164806100
• Email: katarzyna.jerzak[@]sunnybrook.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study, 50 women with either HER2+ or triple negative metastatic breast cancer but no known brain metastases will be recruited at the Sunnybrook Odette Cancer Centre. They will be randomized to undergo either routine MRI screening of their brain every 4 months for 1 year or standard-of-care (MRI only if symptoms of brain metastases develop). Patients will complete questionnaires about quality of life and cancer-related anxiety throughout the study. To determine why some cancers spread to the brain and others do not, blood samples will be collected to analyze the genetic makeup of patients' breast cancers. Finally, a novel MRI imaging technique that detects abnormal metabolism in the brain will be used to help detect brain metastases even earlier than the standard MRI.

If results are promising, we will conduct a large multi-centre randomized trial to determine whether screening for brain metastases can help them live longer with improved quality of life.

Description:

Please see trial details below.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: June 2021
• Est. primary completion date: June 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age =18

2. Triple negative or HER2+ breast cancer (ASCO/CAP guidelines 2018)*

3. MBC, as defined as distant disease outside of the breast and local/regional lymph nodes. Physicians' clinical judgment will be used to determine the possible need for biopsy in confirming a MBC diagnosis. However, biopsy of a metastatic site is not required for pathologic confirmation of stage IV disease.

4. Diagnosis of metastatic disease within 12 weeks prior to study enrollment.

5. No symptoms of BrM or known asymptomatic BrM at study entry.

6. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen may participate.

• This will generally be based on the primary cancer but in the event that a metastatic site is biopsied eligibility will be based on the ER, PR and HER2 profile of the metastasis.

Exclusion Criteria:

1. Inability to participate in an MRI screening program as determined by the patient and/or physician. This may be on the basis of severe claustrophobia, performance status that limits additional testing, or a metal foreign body that would prevent MRI imaging.

2. Inability to provide informed consent. Notably participants who require translators are allowed to enroll.

3. Creatinine clearance <30 mL/min using the Cockcroft-Gault equation.

4. Established need for brain imaging apart from the breast cancer diagnosis (e.g surveillance for an aneurysm).

5. ECOG Performance status >2.

6. Pregnancy.

7. Grade 3+ allergy to Gadavist IV contrast (CTEP Adverse Event Reporting System).

Related Conditions & MeSH terms

• Brain Metastases
• Brain Neoplasms
• Breast Neoplasm
• Breast Neoplasms
• HER2-positive Breast Cancer
• Neoplasm Metastasis
• Triple Negative Breast Cancer
• Triple Negative Breast Neoplasms

Intervention

Diagnostic Test:
• MRI screening
A standard contrast-enhanced MRI and Chemical Exchange Saturation Transfer (CEST) MRI of the brain will be performed at baseline, 4 months, 8 months and 12 months.

Locations

Country	Name	City	State
Canada	Sunnybrook Odette Cancer Centre	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
Sunnybrook Health Sciences Centre	Harvard University

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Proportion of patients with changes in CEST imaging that are suggestive of brain metastases prior to confirmation on contrast-enhanced MRI imaging.	Exploratory outcome.	Baseline, 4-, 8- and 12-months.
Primary	Proportion of eligible patients at the Sunnybrook Odette Cancer Centre (SOCC) who i) agree to enroll in the proposed randomized phase II pilot study, and ii) complete the study protocol.	This outcome is intended to assess the feasibility of a future large, multi-center randomized trial.	15 months.
Secondary	Proportion of patients in the control arm who undergo imaging of the brain with CT or MRI.	This outcome is intended to assess the incidence of screening "contamination" in the control arm of the study.	12 months
Secondary	Incidence of symptomatic brain metastases.	To be assessed in both study arms.	Baseline, 4-, 8- and 12-months.
Secondary	Number of interventions used to treat brain metastases.	To be assessed in both study arms.	15 months
Secondary	Size and location of BrM per patient.	To be assessed in both study arms.	At the time of diagnosis of brain metastases (from enrollment to 15 months)
Secondary	Neurologic-specific quality-of-life (The Functional Assessment of Cancer Therapy-Brain; FACT-BR version 4 tool).	To be assessed in both study arms; 37 questions are rated from a scale of 0 to 4 (total score 0 to 185 where a lower score indicates better quality-of-life)	Baseline, 6 months and 15 months.
Secondary	Overall quality-of-life (EORTC core quality of life questionnaire; EORTC QLQ-C30 version 3 tool).	To be assessed in both study arms; ; 30 questions are rated from a scale of 1 to 4 (total score 30 to 120 where a lower score indicates better quality-of-life)	Baseline, 6 months and 15 months.
Secondary	Cancer-related anxiety (NCI PRO-CTCAE for anxiety).	To be assessed in both study arms.	Baseline, 6 months and 15 months.
Secondary	Time to death due to any cause.	To be assessed in both study arms.	15 months.
Secondary	Time to death due to neurologic progression.	To be assessed in both study arms.	15 months.